Intellia Therapeutics (NTLA) Gross Profit: 2015-2025
Historic Gross Profit for Intellia Therapeutics (NTLA) over the last 11 years, with Sep 2025 value amounting to $13.8 million.
- Intellia Therapeutics' Gross Profit rose 51.27% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.5 million, marking a year-over-year increase of 33.52%. This contributed to the annual value of $57.9 million for FY2024, which is 59.55% up from last year.
- As of Q3 2025, Intellia Therapeutics' Gross Profit stood at $13.8 million, which was down 3.25% from $14.2 million recorded in Q2 2025.
- Over the past 5 years, Intellia Therapeutics' Gross Profit peaked at $28.9 million during Q1 2024, and registered a low of -$1.9 million during Q4 2023.
- Over the past 3 years, Intellia Therapeutics' median Gross Profit value was $12.9 million (recorded in 2024), while the average stood at $12.6 million.
- Its Gross Profit has fluctuated over the past 5 years, first skyrocketed by 4,322.00% in 2022, then slumped by 114.12% in 2023.
- Quarterly analysis of 5 years shows Intellia Therapeutics' Gross Profit stood at $12.9 million in 2021, then rose by 5.59% to $13.6 million in 2022, then crashed by 114.12% to -$1.9 million in 2023, then surged by 771.57% to $12.9 million in 2024, then spiked by 51.27% to $13.8 million in 2025.
- Its Gross Profit was $13.8 million in Q3 2025, compared to $14.2 million in Q2 2025 and $16.6 million in Q1 2025.